Document is current
Any future updates will be listed below
-
Authors
Dosne, Anne-Gaëlle
Valade, Elodie
Goeyvaerts, Nele
De Porre, Peter
Avadhani, Anjali
O’Hagan, Anne
Li, Lilian Y.
Ouellet, Daniele
Perez Ruixo, Juan Jose https://orcid.org/0000-0001-9890-745X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02365597 at ClinicalTrials.govDocuments that mention this clinical trial
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
https://doi.org/10.1007/s00280-021-04381-4
Fibroblast growth factor receptor ( <i>FGFR</i> ) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder
https://doi.org/10.1136/jclinpath-2020-207115
Precision oncology in urothelial cancer
https://doi.org/10.1136/esmoopen-2019-000616
-
Funding
Funding for this research was provided by:
Janssen Research and Development
- License Information
-
More Information
Article History
Received: 23 August 2021
Accepted: 22 November 2021
First Online: 3 January 2022
Declarations
:
: All the authors are or were employees of Janssen Research & Development and shareholders of Johnson & Johnson at the time the analysis was conducted. Currently, EV is an employee of Paraxel, Spain.
: The study included in the analysis was conducted in accordance with the Declaration of Helsinki and in adherence with the good clinical practice guidelines and was approved by the Institutional Review Board.
: Informed consents were obtained from all participants prior to the enrolment.
: Not applicable.
